Sarah had just settled in for the evening when a headline on her phone caught her attention: “FDA approves a new drug for primary IgA nephropathy.”
For someone living with this long-standing kidney condition, the news felt personal. Every follow-up test, every rising protein level in urine, and every conversation with her nephrologist carried a cloud of uncertainty. Like many patients, she often wondered whether her kidneys would continue to decline.
What is Primary IgA Nephropathy?
Primary IgA nephropathy is a kidney disorder caused by abnormal IgA type of antibodies. IgA is one of the major antibody classes produced by the immune system (others include IgM, IgG, IgD, and IgE).Normally, the antibody recognizes any foreign molecule in the body and neutralizes it. In this condition, the IgA molecules themselves are structurally abnormal, and the body mistakenly recognizes them as foreign molecules. This triggers the formation of antibodies against the abnormal IgA, creating immune complexes. These complexes deposit in the kidney tissue and lead to inflammation, manifesting with blood or protein in urine, high blood pressure, and a progressive decline in kidney function. Earlier treatments such as blood-pressure lowering medicines, steroids, and SGLT2 inhibitors helped reduce kidney strain but did not directly address the abnormal IgA production.
What Is Voyxact and how does it work?
Voyxact (sibeprenlimab-szsi) is a monoclonal antibody that addresses the root cause of primary IgA nephropathy by reducing the production of abnormal IgA. It does this by blocking a protein in the body called APRIL (A proliferation-inducing ligand). APRIL normally tells certain immune cells to make more IgA.
By blocking APRIL:
The body makes less of the abnormal IgA antibodies.➡️ Fewer of these bad antibodies reach the kidneys.➡️ There is less inflammation and damage in the kidney filters.
What are the Effects of Voyxact on Kidneys?
The clinical trial that led to the approval of Voyxact included adults who continued to have high levels of protein in their urine despite standard care. The results showed a 50 percent reduction in urinary proteins at month 9. Lower protein levels suggest reduced inflammation and less ongoing kidney injury.
Who May Benefit From Voyxact?
Voyxact may be appropriate for adults with primary IgA nephropathy who continue to have protein in their urine despite treatment with:
- ACE inhibitors or ARBs
- SGLT2 inhibitors
- Steroids or other supportive treatments
It may also be considered earlier in patients who appear to be at higher risk for kidney decline. A doctor may evaluate their kidney function, urine protein levels, blood pressure control, and overall health before deciding whether Voyxact is right for them.
Who Should be Careful When Using Voyxact?
- A person who has an active infection should avoid starting Voyxact until the infection is fully treated.
- A person who is at higher risk for infections should use Voyxact cautiously because it can weaken parts of the immune system.
- A person starting treatment should be monitored for symptoms such as fever, cough, or unusual tiredness, as these may signal an infection.
- A person planning to receive vaccines should avoid live vaccines for 30 days before starting Voyxact and throughout treatment.
How Is Voyxact Given?
Voyxact is administered as a small injection under the skin. Key points include:
- Dosing is once every four weeks.
- The first dose is usually given at the clinic.
- After training, some patients may be able to self-inject at home.
Current Limitations of Voyxact
While Voyxact represents an important step forward, there are still some uncertainties to keep in mind:
- It is not a cure for IgA nephropathy; it helps manage the disease rather than eliminate it.
- Long-term effects on kidney health are still being studied, and more data will emerge over the coming years.
It is not yet approved for children or certain groups such as pregnant women, breastfeeding mothers, and very elderly patients, as safety data in these populations is still limited.
Should You Ask Your Doctor About Voyxact?
If you are undergoing treatment for IgA, it may be worth discussing this medication with your doctor. Consider asking:
- Am I a suitable candidate for Voyxact?
- What kind of improvement should I expect?
- What tests will I need before starting?
- How will we monitor progress?
Conclusion
The FDA approval of Voyxact marks a hopeful moment for people living with primary IgA nephropathy. For the first time, a medication specifically targets the immune mechanism responsible for kidney damage. While ongoing research will clarify its long-term benefits, it already offers a new level of control for many patients.
With early diagnosis, consistent monitoring, and a strong partnership with the healthcare team, patients now have more options and more hope than ever before.
References: